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ABSTRACT
Objective: The aim of this study was to investigate effects of phenolic compounds rich fraction extracted from aerial parts of Salvia frigida on serum 
uric acid (SUA) and xanthine oxidase (XOD) in hyperuricemic mice model.
Methods: A total of 40 albino male mice were equally divided into four groups. The blank group was given vehicles only. The model of hyperuricemia 
was induced by single intraperitoneal injection of UA (250 mg/kg). S. frigida group was pretreated orally with phenolic compounds rich fraction 
(300 mg/kg) for 6 days and one final oral dose was given directly after the UA injection on the 7th day as an acute treatment and the same was 
applied to allopurinol (20 mg/kg) which served as a positive control. 1 h later blood was withdrawn to be tested for SUA, XOD, and creatinine levels. 
Furthermore, the body weights were daily documented before each administration.
Results: The results revealed a highly comparable significant reduction in SUA and XOD in both S. frigida and allopurinol groups without significantly 
affecting serum creatinine compared to model group, also both modestly decreased the body weights of mice.
Conclusion: S. frigida significantly reduces SUA in the hyperuricemic model and may also have a promising effect on weight management.
Keywords: Uric Acid, Xanthine Oxidase, Urate Lowering Therapy, Flavonoids, Quercetin, Allopurinol.
INTRODUCTION
Hyperuricemia defined as the presence of elevated serum UA (SUA) 
concentration. UA is the end product of purine metabolism in human [1]. 
El-Yassin et al. (2012) found that 19% of a sample of Iraqi subjects 
from Karbalaa city has elevated levels of SUA [2]. Hyperuricemia 
complications can lead to gout and nephrolithiasis and increase the risk 
of cardiovascular diseases, metabolic disorders, and chronic kidney 
disease [3-9].
There are currently few approved urate-lowering therapies (ULTs) 
available in clinical practice at the same time they have several drug 
interactions, contraindications, side effects, and sometimes unfortunate 
severe adverse effects. The global rising burden of hyperuricemia 
together with the increased evidence that linked hyperuricemia to the 
pathogenesis of other diseases and the lack of the perfect agent to treat 
it further emphases the importance of the urgent need for developing 
new ULTs.
Natural plant-derived phenolic compounds, especially flavonoids 
have showed potential SUA lowering effect by xanthine oxidase (XOD) 
inhibitory action [10,11] and/or uricosuric effect [10,12] in addition 
to antioxidant and anti-inflammatory effects [10]. The dual effect 
as a XOD inhibitor (XOI) and a free radical scavenger, suggests new 
promising therapeutic perspective to prevent hyperuricemia and its 
complications, as UA can induce oxidative stress, inflammation, and 
tissue injury [10].
Salvia frigida Boiss. (Family: Lamiaceae) exhibited in vitro inhibition to 
XOD [13]. To the best of our knowledge, no in vivo study is available 
to assess its effects on model of hyperuricemia. Accordingly, this study 
has explored S. frigida Boiss. aerial parts ethanolic extract; phenolic 
compounds rich fraction, for potential promising urate lowering effect 
in hyperuricemic mice model.
MATERIALS AND METHODS
Materials
Allopurinol tablets (Aspen, Germany), carboxymethyl cellulose sodium 
salt (CMC-Na) (Panreac, Spain), methanol high-performance liquid 
chromatography (HPLC) grade 99.9% (GCC, UK), myricetin, quercetin, 
and rutin standards (Chengdu Biopurify, China), UA powder (Downs 
development, England), and XOD ELISA kit for mice (Al-Shkairate 
establishments, Jordan) were used. All other chemicals are of the 
highest purity obtained from reputed sources. Animal feeding needle 
curved 20G×1″ (2 mm tip diameter) Reusable (Petsurgical, India), 
Cobas c 111 analyzer (Roche, Switzerland), high performance liquid 
chromatography (HPLC) (Waters, Germany), Rotatory evaporator 
(Buchi, Switzerland), Soxhlet (Labtech, Korea).
Plants
Salvia frigida Boiss. was provided by the Herbarium of Department of 
Biology, College of Science, University of Baghdad.
Animals
A total of 40 apparently healthy albino male mice weighing between 25 
and 30 g were included in the study and were randomly divided into 
four groups (10 mice each). The mice were obtained from the National 
Center for Drug Control and Research/Ministry of Health/Baghdad. 
Each group was kept in a separated plastic cage, had free access to 
water and pellet diet, maintained at 12 h light/dark cycles with room 
temperature (22–25°C), and habituated for a week before starting with 
the in vivo study.
Approval of methods
The study protocol was approved by the Institutional Review Board at 
College of Medicine, Al-Nahrain University. Plant extraction and HPLC 
analysis were conducted at Pharmacognosy Department, College of 
Pharmacy, University of Baghdad.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i4.32096
Research Article
212
Asian J Pharm Clin Res, Vol 12, Issue 4, 2019, 211-217
 Al-Dabbagh et al. 
The in vivo study was conducted at the laboratories of the Pharmacology 
Department/College of Medicine/Al-Nahrain University. The study was 
started during May 2018 and the thesis was completed in December 
2018.
Extraction of plants
Dry powdered aerial parts plant (250 g) was defatted with hexane 
for 24 h then allowed to dry at room temperature. The defatted plant 
materials were extracted with 80% ethanol (1 l) in Soxhlet apparatus 
until complete exhaustion.
The alcoholic extract was evaporated under reduced pressure at a 
temperature not exceeding 40°C to give a residue designated as a crude 
fraction.
Crude fraction was acidified with hydrochloric acid (5%) to pH 2 and 
partitioned (three times) with an equal volume of ethyl acetate to get 
two layers (aqueous acidic layer and ethyl acetate layer).
The ethyl acetate layer designated as fraction 1 was separated and 
evaporated to dryness under reduced pressure and basified with 
300 ml of sodium hydroxide 5% to pH 10 and extracted with chloroform 
in the separatory funnel to get two layers, the aqueous basic layer and 
chloroform layer.
The aqueous basic layer designated as fraction 2 was separated, 
evaporated to dryness and acidified with 5% hydrochloric acid to pH 2 
then extracted with ethyl acetate to get the final fraction designated 
as fraction 3 (F-3) which after being subjected to evaporation process 
represents the phenolic compounds rich fraction that was used for 
formulating oral formula for in vivo administration. The previously 
mentioned procedure is according to Kadhim (2013) [14].
Preliminary qualitative phytochemical analysis
Test for flavonoids
a. NaOH test: To 5 ml from the crude extract was treated with aqueous 
NaOH and HCl, looking for the formation of yellow-orange color [15].
b. Lead acetate test: To a 5 ml of F-3 fraction, 1 ml of 10% lead acetate 
solution was added. The formation of a yellowish-white precipitate 
indicates a positive for flavonoids [15].
Test for phenolic compounds
Ferric chloride test: A little of F-3 fraction was dissolved in distilled water, 
2 ml of 5% ferric chloride solution was added to it. Formation of violet, 
blue or green color indicates the presence of phenolic compounds [16].
Flavonoids identification using HPLC technique
The identification of flavonoids was done with HPLC. The identifications 
were made by comparing the retention times obtained at identical 
chromatographic conditions between extract fraction and standards. 
1 mg from the extracted fraction was dissolved in 1 ml ethyl acetate, 
and 20 μl from this solution was injected into the HPLC. The standards 
were prepared as solutions with a concentration of 1 mg/ml for each. 
The solvent used for dissolving the standards was methanol. 20 μl from 
each solution was injected into the HPLC for each run in HPLC.
The experimental conditions of HPLC were:
• Mobile phase: Mixture of methanol:water (70:30) [17].
• Column temperature 25°C.
• Column ODS C18 (250 mm×4.6 mm, 5 μm particle size).
• Flow rate 1 ml/min.
• Detection wavelength 265 nm [18].
Experimental design
The induction of hyperuricemia model was done by a single 
intraperitoneal (i.p.) injection of UA, at a dose of 250 mg/kg [19] in 
0.5% w/v CMC-Na/normal saline, to be given on the 7th day of the 
study right before the oral administration of either tested S. frigida F-3 
fraction, vehicles, or allopurinol.
The study groups were:
• Group 1: Normal control group (blank group) was given vehicle “0.5% 
CMC-Na/Distal water” 0.2 ml/20 g/day orally for 7 days + single i.p. 
injection of vehicle “0.5% CMC-Na/normal saline” 0.2 ml/20 g on 
the 7th day of the study.
• Group 2: Induced non-treated control group (model group) was 
given vehicle “0.5% CMC-Na/Distal water” 0.2 ml/20 g/day orally 
for 7 days + single i.p. injection of UA 250 mg/kg on the 7th day of 
the study.
• Group 3: The positive control group (allopurinol group) was given 
allopurinol 20 mg/kg/day orally for 7 days + single i.p. injection of 
UA 250 mg/kg on the 7th day of the study.
• Group 4: S. frigida treatment group (S. frigida group) was given 
phenolic compounds rich fraction “F-3” of S. frigida extract 
300 mg/kg/day orally for 7 days + single i.p. injection of UA 
250 mg/kg on the 7th day of the study.
The oral vehicles, S. frigida extract, and allopurinol were given daily, 
every 24 h for 7 consecutive days. The preparation of CMC-Na 0.5% w/v 
colloidal solution was based on Kamal et al. (2017) [20] and the United 
States Pharmacopeia weight variation test was done on allopurinol 
tablets to ensure proper allopurinol weighing. All the medications were 
freshly prepared and were given according to the animal body weight 
which was measured directly before each administration.
Blood collection
On the 7th day, 1 h after the last administration, blood samples were 
collected by cardiac puncture under anesthesia using chloroform. Blood 
samples were allowed to clot for 1 h at room temperature, then were 
centrifuged to obtain serum for measuring UA and creatinine by cobas c 
111 analyzer; furthermore, 150 μl of serum were stored at −80°C (until 
testing it later on for XOD by following the kit instructions).
Statistical analysis
The statistical analysis of this study was performed with the statistical 
package for the social sciences (SPSS) version 23.0 and Microsoft Excel 
2016. Numerical data were expressed as mean ± standard deviation 
(SD) and were analyzed using independent Student’s t-test (unpaired 
t-test) for comparison between two groups. Pearson correlation was 
done between SUA and XOD and expressed as r (correlation coefficient) 
and its p value. Paired t-test was used to compare body weight at day 7 
(d7) and day 1 (d1) within each study group. For all of the previously 
mentioned statistical tests, it was considered significant if p<0.05 and 
highly significant if p<0.001.
RESULTS
The mean±SD for SUA, creatinine, XOD, and the difference in body 
weight between d7 and d1 were measured for the blank group, model 
group, allopurinol group, and S. frigida group.
Analysis of unpaired t-test revealed a highly significant increase 
(p<0.001) in the level of UA in model group in comparison with the 
blank group. Furthermore, a statistically significant increases (p<0.05) 
in XOD in model group compared to blank group. While no statistically 
significant difference regarding other parameters; almost no change in 
creatinine levels and very close weight gain occurred in both groups 
(Table 1).
The results showed a highly significant reduction (p<0.001) in UA 
level in both allopurinol group and S. frigida group compared to the 
model group. On the other hand, no significant change in creatinine 
levels for both groups in comparison with the model group. Serum 
XOD appeared to be statistically significant (p<0.05) lower in S. frigida 
group and highly significant (p<0.001) lower in the allopurinol group 
compared to the model group. There were statistically significant 
(p<0.05) decrease in body weight in both S. frigida and allopurinol 
groups compared to the model group. Numerical results are reviewed 
in Table 2.
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Pearson correlation between SUA and XOD revealed that only the 
allopurinol group appears to have a statistically significant (p<0.05) 
positive correlation between SUA and XOD. The resultant correlation 
coefficients and their significance for each group are shown in Table 3.
The mean±SD for body weight at d1 and d7 were measured for each 
study group, illustrated in Fig. 1. Analysis of paired t-test revealed a 
modest decrease in body weight in both allopurinol and S. frigida group 
while statistically significant (p<0.05) weight gain in both blank and 
model group were documented.
Preliminary qualitative phytochemical analysis results
Phytochemical screening was done using colors and precipitates 
formation after following standard tests for detecting the phytochemicals 
of interest: Phenolic compounds and flavonoids. S. frigida achieved 
positive tests for NaOH (yellow-orange), lead acetate (yellow precipitate), 
and ferric chloride (dark green) tests.
HPLC results
The phenolic compounds of S. frigida F-3 fraction were identified by HPLC 
method by comparing them with standard compounds retention times 
obtained at identical chromatographic conditions of the analyzed samples 
and authentic standards. HPLC retention times for matching flavonoids 
were 2.48, 3.11, and 4.48 for rutin, quercetin, and myricetin standards, 
respectively. The information obtained from the HPLC method of analysis 
revealed that S. frigida is very rich in quercetin. Other flavonols; rutin and 
myricetin, were also detected still the highest peak was not identified. The 
peaks extent of S. frigida components is shown in Fig. 2.
DISCUSSION
Hyperuricemia prevalence has increased dramatically throughout the 
past century reaching to the current dates. It is now a major concern not 
only because of risking for gout emergence but also it has been recently 
linked to developing chronic kidney diseases, cardiovascular diseases, 
and metabolic disorders. Very few ULTs are available with various 
contraindications and unfortunate adverse effects. In recent years, natural 
phenolic compounds; especially flavonoids and phenolic acids have been 
found to possess a promising inhibitory effect on XOD and can decrease 
UA level with the favorable safety profile and additional antioxidant effect.
This study revealed for the first time major flavonoids constituents 
of S. frigida. The Preliminary analysis results showed that flavonoids 
class is the richest component of the phenolic compounds content of 
Table 1: Comparison between Blank group (Gp1) and model group (Gp2) in relation to serum uric acid, creatinine, xanthine oxidase, 
and the difference in body weight by unpaired t-test
Parameters n=10 Blank (Gp1) vehicles only Model (Gp2) UA 250 mg/kg
Serum uric acid (mg/dl) Mean±SD 2.05±0.21 3.63±0.23
p <0.001***
Serum creatinine (mg/dl) Mean±SD 0.18±0.04 0.18±0.06
P 1.000
Serum XOD1 (pg/ml) Mean±SD 490.25±167.71 615.05±76.07
P 0.046*
difference in d7 and d1 weight2 (g) Mean±SD 1.41±0.85 1.12±0.89
P 0.469
The hyperuricemic mice model was induced by a single intraperitoneal injection of UA on the 7th day of the study while injecting vehicle to the Blank group. Both groups 
were given oral vehicles throughout the 7 days. 1Xanthine oxidase, 2difference in body weight between d7 and d1, *denotes significant difference at P<0.05, ***denotes 
highly significant difference at P<0.001. UA: Uric acid, d7: Day seven, d1: Day one, SD: Standard deviation
Table 2: Comparison between model group (Gp2), allopurinol group (Gp3), and Salvia frigida group (Gp4) in relation to serum uric acid, 
creatinine, xanthine oxidase, and the difference in body weight by unpaired t-test
Parameters n=10 Model (Gp2) UA 250 mg/kg Allopurinol (Gp3) 20 mg/kg+UA Salvia frigida (Gp4) 300 mg/kg+UA
Serum uric acid 
(mg/dl)








Mean±SD 615.05±76.07 431.1±62.52 473.2±92.11
P <0.001*** 0.001*
Difference in d7 and 
d1 weight2 (g)`
Mean±SD 1.12±0.89 −0.75±1.18 −0.52±1.18
P 0.001* 0.002*
The hyperuricemic mice model was induced by a single intraperitoneal injection of UA on the 7th day of the study while giving oral vehicle throughout the 7 days. 
Allopurinol and Salvia frigida (phenolic compounds rich fraction) were given orally for 7 days (+ the UA injection on the 7th day) to Gp3 and Gp4 mice groups, 
respectively. 1Xanthine oxidase, 2difference in body weight between d7 and d1. *Denotes significant difference at P<0.05 compared to model group, ***Denotes highly 
significant difference at P<0.001 compared to model group. UA: Uric acid, d7: Day seven, d1: Day one, SD: Standard deviation
Table 3: Pearson correlation between serum uric acid and serum xanthine oxidase within all study groups
n=10 Serum uric acid (mg/dl)




Salvia frigida (Gp4) 
300 mg/kg+UA
Serum XOD1 (pg/ml)
r2 −0.089 −0.081 0.688 0.597
P 0.807 0.815 0.028* 0.069
*Denotes significance at P<0.05. The hyperuricemic mice model was induced by a single intraperitoneal injection of UA on the 7th day of the study while giving oral 
vehicle throughout the 7 days. Blank group mice (Gp1) were given vehicles only. Allopurinol and phenolic compounds rich fractions from Salvia frigida were given orally 
for 7 days (+ the UA injection on the 7th day) to Gp3 and Gp4 mice groups, respectively. 1Xanthine oxidase, 2correlation coefficient. UA: Uric acid, d7: Day seven, d1: Day 
one, SD: Standard deviation
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S. frigida. Quercetin is abundant in S. frigida; it appeared as the second 
highest peak. Still, the highest peak and several other peaks were not 
identified. Other detected flavonols in high concentrations were rutin 
and myricetin. The pharmacological activity of S. frigida phenolic 
compounds rich fraction (300 mg/kg/day) appears to be due to those 
three major flavonoids constituents (quercetin, rutin, and myricetin) in 
addition to the unidentified highest peak.
In this study, single i.p. injection of UA (250 mg/kg) on the 7th day of 
the study to model group while giving vehicle orally throughout the 
previous days was resulted in marked hyperuricemia, being measured 
after 1 h of the last administration, compared to blank group, with a 
highly significant increase in SUA levels (Table 1). These findings are 
in agreement with reported protocol by Chen et al. (2006) who found 
a significant increase in SUA concentration even after 10 min from 
injecting the same dose into mice [19].
To the best of our knowledge, the current study is the first to report 
serum XOD concentration in mice under such conditions. It revealed that 
circulating XOD has mildly increased to a level that reaches statistical 
significance. The mildly elevated levels of mean serum XOD enzyme may 
indicate increased permeability, damage, or necrosis of tissues which is 
not only a marker of hepatic or intestinal injury but it can also result 
from a variety of remote organ damage as a consequence of oxidative 
injury [21,22]. This probably occurred in some, but not all ten animals 
as the results also showed a very week negative correlation (though 
have not reached statistical significance) between SUA and XOD levels 
in both blank and model groups (Table 3). It has been established that 
UA acts normally as serum antioxidant [23]; nevertheless, UA may give 
pro-oxidant activity, mainly intracellularly [24]. It exerts pro-oxidant 
deleterious effect under several conditions; most importantly when 
presents at high levels even in the upper two-thirds of physiological 
ranges [25]. Furthermore, the pro-inflammatory action of UA may 
induce cell transformation through reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) generation. Besides, intracellular UA 
may contribute to decreasing the level of XOD expression [26]. Moreover, 
UA can actually inhibit XOD and thereby act as a feedback inhibitor of 
the enzyme; this effect is associated with increased ROS formation [21]. 
UA may exert a pro-oxidant activity within the cell mainly, possibly 
due to the free radicals derived from its reaction with ROS, RNS, and 
nitric oxide (NO), in particular in the presence of myeloperoxidase [24]. 
Hyperuricemia causes uncoupling of endothelial NO synthase which 
increases superoxide radical production [25]. UA-derived free radicals 
have been associated with several effects such as reduced availability 
of NO, cyclooxygenase-2 expression and up-regulation of the renin/
angiotensin pathway, platelet activation, migration and proliferation of 
Fig. 1: Comparison between body weight at day 1 (d1) and at 
d7 within each study group by paired t-test. The hyperuricemic 
mice model was induced by a single intraperitoneal injection of 
uric acid (UA) 250 mg/kg on the 7th day of the study while giving 
oral vehicle throughout the 7 days. Blank group mice were given 
vehicles only. Allopurinol 20 mg/kg and phenolic compounds rich 
fractions (300 mg/kg) from S. frigida were given orally for 7 days 
(+ the UA injection on the 7th day) to their corresponding mice 
groups, respectively. Data represent mean± standard deviation 
for 10 mice. *Denotes significant difference at p<0.05 compared 
with d1
Fig. 2: High-performance liquid chromatography of Salvia frigida
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vascular myocytes, and production of pro-inflammatory cytokines by 
macrophages [26].
Recently, Wang et al. (2016) have found a significant increase in hepatic 
XOD activity and protein levels in hyperuricemic mice model [27] while 
Qin et al. (2018) have found a significant increase in both serum and 
hepatic XOD activities and hepatic XOD protein levels in hyperuricemic 
mice model [28]. Serum XOD enzyme activity has significantly 
increased in several studies using various hyperuricemic models in 
rodents compared to blank controls [19,29]. Increased XOD activity 
could induce oxidative stress through ROS and UA production. XOD 
pathway is an important path in the oxidative damage to tissues. The 
UA conversion from hypoxanthine and xanthine by XOD is accompanied 
by the generation of superoxide anion and hydrogen peroxide and 
eventually give rise to hydroxyl radical through the Haber-Weiss and 
Fenton reactions in the presence of transition metals [4,26,30-32]. 
These cytotoxic ROS are highly reactive and can directly oxidize 
macromolecules including DNA, protein, and lipids [30,31] which 
may result in cellular damage when produced in large amounts [32]. 
Furthermore, XOD activities may produce RNS, although other enzymes 
are implicated in the generation of these [26] as with highly reactive 
peroxynitrite (OONO-) [33,34]. Accordingly, in this study, lipid 
peroxidation mediated by ROS and RNS has probably caused cell 
membrane damage leading to the release of XOD into the serum.
Humans have only 1% activity of XOD compared with other mammals. 
The decrease in XOD activity is one likely evolutionary adaptation to 
uricase loss in humans [35] as the sudden knockout of uricase in mice 
appears to be fatal due to striking increase in SUA levels which cause 
acute urate nephropathy and renal failure [36]. No significant change in 
creatinine occurred in model group as the elevation in the serum levels 
of creatinine can be only noted after extensive kidney injury involving 
the damage of approximately half of the kidney nephrons [37].
As expected, changes in body weight after 1 week were kind of similar 
in both model and blank groups. This observation is consistent with 
Jiang et al. (2017) as they have injected mice intraperitoneally with 
potassium oxonate (300 mg/kg) to induce hyperuricemia on the 
7th day of the study while giving normal saline to the blank group, 
noting no significant difference regarding weight gain between the two 
groups [38].
In the present study, mice were pretreated orally for 6 days with either 
phenolic compounds rich fraction extracted from S. frigida (300 mg/kg) 
or allopurinol (20 mg/kg) and on the 7th day the mice were given, 
immediately after the single UA i.p. injection, one final oral dose as an 
acute treatment. The results revealed excellent hypouricemic effect 
exerted by S. frigida as both S. frigida and allopurinol accomplished 
quite similar highly significant SUA reduction after 1 h treatment 
compared to the model group (Table 2). As it has been previously 
reported that S. frigida exert excellent in vitro inhibition to XOD (93.2%) 
compared to allopurinol (80.52%) [13].
The resultant in vivo hypouricemic effect that was achieved by S. frigida 
is probably attributed to XOI effect exhibited by its high flavonoids 
content. Quercetin probably contributes to the majority of the effect 
as it represents one of the major constituents of the in vivo tested F-3 
fraction and to rutin and myricetin to a lower extent. These conclusions 
are consistent with several previous studies showing hypouricemic and 
XOD inhibitory effect exerted by those three flavonols [39,40].
Allopurinol results agree with Qin et al. (2018) as they have shown that 
allopurinol (20 mg/kg), being orally administered to mice for 7 days, 
results in significant reduction in SUA level compared to model group 
with significant inhibition to XOD activity [28].
Another hypothesis behind the hypouricemic effect is proposed by the 
current study which is a decrease in XOD level equals a decrease in its 
activity (one enzyme and one reaction) leading to further lowering in 
UA production. Both S. frigida and allopurinol significantly lowered 
XOD serum level compared to the model group.
In most biological environments, enzyme concentration is lower than 
the concentration of its substrate. As long as this is true, there is a 
directly proportional to relationship between enzyme concentration 
and its activity. In most situations, decreasing enzyme concentration 
has a direct influence on its activity since each enzyme molecule is 
able to catalyze only one reaction at a time. In other words, the rate 
of the reaction decreases as enzyme concentration decreases [41]. 
Furthermore, metabolic labeling studies indicate that H₂O₂ stimulate 
the conversion of xanthine dehydrogenase to XOD [42]. Hence, 
allopurinol’s known XOD activity inhibition and S. frigida probable XOD 
activity inhibition have resulted in decreasing H₂O₂ production thus 
decreasing XOD serum presence.
Our hypothesis may also be supported by the correlation results 
(Table 3) as it obviously showed a positive correlation between UA 
and XOD expression in both S. frigida and allopurinol groups compared 
to negative ones in both blank and model groups. Although only 
allopurinol showed statistical significance still, S. frigida showed very 
close results to reach significance which might only needed a couple of 
further doses. Still, further investigation is needed for confirming such 
effects and its extent and for revealing the mechanism behind it.
The current study revealed that S. frigida and allopurinol probably 
prevented organs damage and consequent XOD leak to serum as they 
both significantly lowered serum XOD level compared to the model 
group. This may be attributed to S. frigida significant antioxidant activity 
as shown by its remarkable scavenging effect against 2,2-diphenyl-
1-picrylhydrazyl radical [13]. Likewise, quercetin and rutin have 
strong antioxidant activities [43]. While the mechanism behind 
allopurinol protection against UA-induced probable tissue damage 
is that allopurinol is not only capable of inhibiting XOD activity and 
reducing UA levels but also it was proven to significantly reduce serum 
malondialdehyde (MDA) hence further decreases oxidative stress [44].
Analysis of unpaired t-test showed significant growth restraint in both 
allopurinol and S. frigida groups compared to the model group (Table 2). 
However, the analysis of paired t-test revealed a non-significant 
decrease in body weight within both allopurinol and S. frigida groups 
(Fig. 1).
Emerging evidence and correlations have linked UA level with body 
weight. Uricase loss and the consequent increase in SUA level have 
been hypothesized to give another survival advantage to hominoids. 
The increased SUA levels may lead to obesity, fatty liver, metabolic 
syndrome, and diabetes. Hence, uricase knockout subjects could more 
easily overcome starvation periods [45]. In a clinical study, enrolling 
patients with cardiac diseases, a positive correlation was detected 
between the plasma level of XOD activity and B-type natriuretic peptide, 
as well as with body mass index [46].
In mice, adipose tissue has a very high comparable level of xanthine 
oxidoreductase (XOR) expression to that of the liver and small 
intestine. Furthermore, XOR activity is higher in obese mice fat tissue 
than in healthy controls [47]. Adipogenesis, XOR expression, and 
amount of UA were increased by subjecting human mesenchymal 
stem cell-derived adipocytes to fructose. Allopurinol inhibited those 
effects. Directly treating adipocytes with UA also resulted in enhanced 
adipogenesis [48]. XOR activity has been portrayed as involved in 
pre-adipocyte differentiation and adipogenesis in studies carried out 
in cultured cells and XOD gene knockout mice [49]. Negative effects 
such as adipogenesis, inflammation, and hypertension are induced 
by XOR activity on purine metabolism [26]. These results suggest 
a fundamental role for XOD activity-derived oxidative stress in UA-
mediated adipogenesis. Interestingly, it has been hypothesized that XOR 
has a protective role in adipose tissue when the environment allows 
it to function as nitrate reductase as an adaptive response to obesity-
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consequent hypoxia in fat tissue by activating the reprogramming 
that leads to browning of the white fat tissue and anti-hypertensive 
activity [26].
Rutin administration can reduce the mass of adipose tissue and 
body weight in an obese rat model. Rutin was found to increase 
mitochondrial DNA content, mitochondrial size, and gene expression 
related to mitochondrial biogenesis (peroxisome proliferator-activated 
receptor gamma coactivator-1α, transcription factor A, nuclear 
respiratory factor-1, and nicotinamide adenine dinucleotide-dependent 
deacetylase) in skeletal muscle [50].
Allopurinol side effects include nausea, diarrhea, and gastrointestinal 
intolerance which might also contribute to the weight loss in allopurinol 
group. Allopurinol results in the present study are in agreement with 
a previous work that found 7 days allopurinol therapy to significantly 
inhibit weight growth in hyperuricemic mice model [38].
CONCLUSION
S. frigida Boiss. and allopurinol have achieved highly similar results with 
a highly significant reduction in SUA compared to hyperuricemic mice 
model; making S. frigida aerial parts phenolic compounds rich fraction 
an excellent candidate for further exploration in the goal of developing 
newer and possibly safer urate-lowering therapy. Furthermore, 
S. frigida mildly decreased body weight of mice; such modest action 
suggests a useful application in developing weight control therapy from 
S. frigida phenolic compounds content.
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